A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

NCT02338843 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Catecholamine-resistant Hypotension (CRH)
Distributive Shock
High Output Shock
Sepsis

Interventions

DRUG: LJPC-501
DRUG: Placebo

Sponsor

La Jolla Pharmaceutical Company